Related Experiment Video

Updated: Jan 24, 2026

Examining Changes in HRV and Emotion Following Artmaking with Three Different Art Materials
06:24

Examining Changes in HRV and Emotion Following Artmaking with Three Different Art Materials

Published on: January 11, 2020

6.7K

State of the art in immunotherapy of neuroblastoma

Parnian Jabbari1,2, Sara Hanaei1,2, Nima Rezaei1,3,2

  • 1Research Center for Immunodeficiencies (RCID), Children's Medical Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

Immunotherapy
|May 17, 2019
PubMed

Insights

Neuroblastoma immunotherapy has advanced with tumor-associated targets like the MYCN gene and GD2 antigen. While effective in children, research continues for broader applications and improved treatments.

Area of Science:

  • Pediatric Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Neuroblastoma (NB) is a prevalent and aggressive childhood cancer.
  • Therapeutic strategies have evolved to include immunotherapy alongside chemotherapy.
  • Molecular discoveries have identified key targets such as the MYCN gene and GD2 antigen.

Purpose of the Study:

  • To review the evolution and current landscape of neuroblastoma immunotherapy.
  • To highlight the significance of MYCN and GD2 as therapeutic targets.
  • To discuss the limitations and future directions in neuroblastoma treatment.

Main Methods:

  • Review of existing literature on neuroblastoma immunotherapy.
  • Analysis of studies targeting MYCN and GD2 antigens.
  • Examination of clinical trials involving immunotherapeutic agents.

Main Results:

  • The MYCN gene and GD2 surface antigen are crucial discoveries for neuroblastoma immunotherapy.
  • GD2-targeted therapies, including monoclonal antibodies, have shown promise in clinical trials, particularly for pediatric NB.
  • Current immunotherapies show limitations, especially in adult-onset neuroblastoma, necessitating further research.

Conclusions:

  • Immunotherapy represents a significant advancement in neuroblastoma treatment, especially in pediatric cases.
  • Targeting antigens like GD2 has improved patient outcomes but is not universally effective.
  • Ongoing research focuses on identifying novel antigens and enhancing therapeutic efficacy for all neuroblastoma patients.
Keywords:
cancerchimeric antibody receptor T cellsimmunotherapymonoclonal antibodiesneuroblastoma

More Related Videos

Zebrafish Model of Neuroblastoma Metastasis05:20

Zebrafish Model of Neuroblastoma Metastasis

Published on: March 14, 2021

3.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
The Sense of Self: Reflected Self-Appraisal and Social Comparison02:57

The Sense of Self: Reflected Self-Appraisal and Social Comparison

According to Charles Cooley, we base our image on what we think other people see (Cooley 1902). We imagine how we must appear to others, then react to this speculation. We don certain clothes, prepare our hair in a particular manner, wear makeup, use cologne, and the like—all with the notion that our presentation of ourselves is going to affect how others perceive us. We expect a certain reaction, and, if lucky, we get the one we desire and feel good about it. But more than that, Cooley...
55.6K